Introduction:
Rentschler Biopharma plans for the new biopharma manufacturing centre (RBMC) facility at its manufacturing site in Massachusetts, USA.
Features:
The new, state-of-the-art RBMC introduces an additional 22,000 square feet of manufacturing cleanroom space and accommodates four new 2,000 L single-use bioreactors.
The existing site has transitioned from a single-product commercial facility to producing multiple products using an intricate bioreactor setup of up to 500 L capacity.
This expansion marks the largest in over 150 years and will effectively double Rentschler biopharma's global cGMP capacity. The facility will primarily concentrate on the commercial production of highly complex molecules for international markets.
The RBMC facility is designed for easy adaptability, aligning with evolving requirements, in expanding international capabilities to delivering comprehensive development and production solutions for the biopharmaceutical sector.
The biopharma manufacturing facility is scheduled to be operational in the second half of 2024.
Specifications:
Name Rentschler Biopharma
Type New Construction
Year 2024
